SecBot SecBot
6-K ·Filed May 29, 2026

AZN

ASTRAZENECA PLC
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago SEC0001654954-26-005498
Notable filing: 6-K
Actionable Insight ▲ Bullish

This approval opens a new, large early-stage bladder cancer market for Imfinzi with no direct immunotherapy competitor in BCG-naïve high-risk NMIBC. Monitor EU/Japan regulatory decisions and physician adoption rates; the VOLGA trial readout last week further strengthens Imfinzi's bladder cancer franchise. Expect modest upward revenue revisions from analysts.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$185.49
T+0 close · May 29, 2026 · via day close
Latest settled
−10.14%
T+60 · $166.68
Vs SPY
−11.06%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 29 $185.49entry
  2. T+1 · 6mo ago −3.20%α −3.46% · $179.55
  3. T+5 · 6mo ago +0.24%α +2.76% · $185.93
  4. T+20 · 5mo ago +1.58%α +5.21% · $188.41
  5. T+60 · 3mo ago −10.14%α −11.06% · $166.68

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

AstraZeneca announced FDA approval of Imfinzi (durvalumab) in combination with BCG for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC), based on the POTOMAC Phase III trial showing a 32% reduction in risk of recurrence, progression, or death. This is the first immunotherapy combination approved in this setting in over 30 years, expanding Imfinzi's label into an early-stage bladder cancer indication with over 31,000 US patients treated annually.

Key Facts

  • FDA approved Imfinzi + BCG for BCG-naïve, high-risk NMIBC, the first immunotherapy combination in this setting in over 30 years.
  • POTOMAC Phase III trial showed 32% risk reduction (DFS HR 0.68, 95% CI 0.50-0.93, p=0.0154) with median follow-up >5 years.
  • Over 31,000 US patients were treated for high-risk NMIBC in 2024; up to 80% of high-risk patients experience recurrence within 5 years.
  • Regulatory submissions under review in EU, Japan, and other countries.
  • Safety profile consistent with known profiles; no new safety signals; no meaningful impact on quality of life.

Financial Impact

Expands Imfinzi addressable market into early-stage bladder cancer; US high-risk NMIBC population ~31,000 patients annually; first-to-market immunotherapy combination in this setting.

revenuemarket share

Risk Factors

  • Competition from other checkpoint inhibitors or novel agents in NMIBC could emerge.
  • Reimbursement and pricing dynamics may limit uptake.
  • Long-term OS data not yet mature; DFS benefit may not fully translate to survival advantage.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
83% bullish (36 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-005498
Document: 0001654954-26-005498-index-headers.html0001654954-26-005498
Document: 0001654954-26-005498-index.html0001654954-26-005498
Document: 0001654954-26-005498.txt0001654954-26-005498

Track record

77 reports on AZN

Performance horizon

18 of 37 bullish or bearish reports moved the stock their way by T+5. Best: +20.72% at T+60 after the Aug 17, 2026 report. 28 of 37 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 6/10 Entry price pending
  2. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.55 Now $184.45 −0.59% settles Nov 23
  3. Nov 16, 2026today 6-K Bullish 6/10 Entry $185.31 Now $184.45 −0.46% settles Nov 23
  4. Nov 16, 2026today 6-K Bullish 5/10 Entry $185.09 Now $184.45 −0.35% settles Nov 23
  5. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $186.85 to $184.38 Now $184.45 −1.28% ▼ −1.32% −4.61% vs SPY
  6. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  7. Nov 2, 202614d ago 6-K Neutral 1/10 Entry $186.58 to $189.39 Now $184.45 −1.14% ▲ +1.51% +1.43% vs SPY
  8. Oct 30, 202617d ago 6-K Neutral 5/10 Entry $186.65 to $186.43 Now $184.45 −1.18% ▼ −0.12% +2.59% vs SPY
  9. Oct 27, 202620d ago 6-K Bullish 5/10 Entry $170.08 to $183.88 Now $184.45 +8.45% ▲ +8.11% +10.10% vs SPY
  10. Oct 22, 202625d ago 6-K Bullish 6/10 Entry $172.57 to $173.46 Now $184.45 +6.88% ▲ +0.51% −0.19% vs SPY
Showing 10 of 77

US Market Status

Market Closed · Opens Wed (12h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 29, 2026